Label: FABIOR- tazarotene aerosol, foam

  • NDC Code(s): 51862-295-10, 51862-295-50
  • Packager: Mayne Pharma
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated May 9, 2024

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use FABIOR Foam safely and effectively. See full prescribing information for FABIOR Foam. FABIOR (tazarotene) Foam, 0 .1%, for topical ...
  • Table of Contents
    Table of Contents
  • 1 INDICATIONS AND USAGE
    FABIOR® (tazarotene) Foam, 0.1% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.
  • 2 DOSAGE AND ADMINISTRATION
    FABIOR Foam is for topical use only. FABIOR Foam is not for oral, ophthalmic, or intravaginal use. FABIOR Foam should be applied once daily in the evening after washing with a mild cleanser and ...
  • 3 DOSAGE FORMS AND STRENGTHS
    0.1%, white to off-white foam
  • 4 CONTRAINDICATIONS
    FABIOR Foam is contraindicated in pregnancy. FABIOR Foam may cause fetal harm when administered to a pregnant woman. Tazarotene elicits teratogenic and developmental effects associated with ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Fetal Risk - Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure ...
  • 6 ADVERSE REACTIONS
    6.1 Clinical Trials Experience - Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly ...
  • 7 DRUG INTERACTIONS
    No formal drug-drug interaction studies were conducted with FABIOR Foam. Concomitant dermatologic medications and cosmetics that have a strong drying effect should be avoided. It is recommended ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - FABIOR Foam is contraindicated in pregnancy [see Contraindications (4)]. There are no adequate and well-controlled studies with FABIOR Foam in pregnant women. FABIOR Foam is ...
  • 10 OVERDOSAGE
    Excessive topical application of FABIOR Foam may lead to marked redness, peeling, or discomfort. [see Warnings and Precautions (5.2)]. Management of accidental ingestion or excessive application ...
  • 11 DESCRIPTION
    FABIOR (tazarotene) Foam, 0.1% contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical use only. Chemically, tazarotene is ethyl ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - Tazarotene is a retinoid prodrug that is converted to its active form, the cognate carboxylic acid of tazarotene, by rapid deesterification in animals and man ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Carcinogenesis: A long-term study of tazarotene following oral administration of 0.025, 0.050, and 0.125 mg/kg/day to rats showed ...
  • 14 CLINICAL STUDIES
    In 2 multi-center, randomized, double-blind, vehicle-controlled trials, a total of 1,485 subjects with moderate-to-severe acne vulgaris were randomized 1:1 to FABIOR Foam or vehicle applied once ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    How Supplied: FABIOR Foam, 0.1% (1 mg/g) is a white to off-white foam, supplied as follows: 100-g aluminum canNDC 51862-295-10 - Storage and Handling: Store at 20°C to 25°C (68°F ...
  • 17 PATIENT COUNSELING INFORMATION
    See FDA-approved patient labeling (Patient Information). Inform the patient of the following: Fetal risk associated with FABIOR Foam for females of childbearing potential. Advise patients to use ...
  • SPL UNCLASSIFIED SECTION
    FABIOR is a registered trademark of Mayne Pharma LLC. ©2016 Mayne Pharma All rights reserved. Distributed by: Mayne Pharma - Raleigh, NC 27609 - 141298
  • Patient Information FABIOR® (fab' ee ore) (tazarotene)Foam
    IMPORTANT: For skin use only. Do not get FABIOR Foam in your eyes, mouth, or vagina. Read the Patient Information that comes with FABIOR Foam before you start using it and each time you get a ...
  • PRINCIPAL DISPLAY PANEL - 100 g Can Carton
    NDC 51862-295-10 - Fabior® (tazarotene) Foam, 0.1% 100 grams - Rx only - For topical use only - STORE UPRIGHT - mayne pharma - Recyclable - Aluminum - Container
  • INGREDIENTS AND APPEARANCE
    Product Information